ROS1 and non-small cell lung carcinoma: This was accomplished using tumor samples from a NSCLC patient who became resistant to crizotinib and a NSCLC cell line that we made resistant to ROS1 inhibition by continuous culture in the ROS1 inhibitor TAE684.